SAB Biotherapeutics
Immunology & Inflammation Therapeutics · Biologics & Biosimilars
2open roles
$182.5Mraised in 2 rounds
2020founded
28stories in the press
Jobs
≈ $77k – $154k per year (Estimated) · Remote (likely United States) · Full-Time · 5+ years exp
GCP
Life Sciences
GMP
GLP
MedTech
CAPA
Apply
$295k – $315k per year · Remote (likely United States) · Full-Time · 5+ years exp
E2B
Life Sciences
ICH Guidelines
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$315k
Typical range
$315k
Open positions
1
1
Jobs
Architect
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Architect | 1 | $315k | $315k |
Highest paying role
Executive Director, Pharmacovigilance (PV), Remote
$315k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
2
0 opened / 0 closed in 30 days
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Industrial Engineering
50% ▲
Biotech
50% ▲
People
Samuel Reich
Executive Officer, Director
Eddie Sullivan
Executive Officer, Director
Katie Ellias
Director
Scott Giberson
Director
Christine Hamilton
Director
David Link
Director
Erick Lucera
Director
Andrew Moin
Director
William Polvino
Director
Jay Skyler
Director
Jeffrey Spragens
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at SAB Biotherapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
6
Postings analysed
2
Stack modernity
53/100
Cloud & platforms
E2B
GCP
Practices & domains
CAPA
GLP
GMP
ICH Guidelines
Sign in to see how your skills match this stack
Sign In
News
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
Executives from Healios and SAB Biotherapeutics (NASDAQ:SABS) outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for commercial manufacturing. Healios Chief Financial Offi
Read more
Report
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today anno
Read more
Report
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetesMIAMI, Oct. 13...
Read more
Report
SAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up
SAB Biotherapeutics, Inc. (SABS) announced that the U.S. FDA has granted Fast Track designation to SAB-142 for the treatment of patients with Stage 3 Type 1 Diabetes.
Read more
Report
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a full...
Read more
Report
SAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of Diabetes
Read more
Report
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today ann
Read more
Report
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Miami Beach
United States
HQ
Contact Us
777 W 41st St. Suite 401 Miami Beach, FL 33140